Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Sprache: | |
| Veröffentlicht: |
Zenodo
2026
|
| Schlagworte: | |
| Online-Zugang: | https://doi.org/10.5281/zenodo.20326080 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Inhaltsangabe:
- <p class="MsoNormal"><strong><span>Background: </span></strong><span>Type 2 Diabetes Mellitus (T2DM) in the setting of cardiovascular and metabolic comorbidities presents a complex therapeutic challenge. The CDC (Comprehensive Diabetes Care) Panchakarma Protocol — integrating Snehan, Swedhan, and Basti Panchakarma therapies with the 800-kcal Prameha Diet Box and individualized oral Ayurvedic herbal medications — was evaluated in a real-world cohort with a high prevalence of comorbid hypertension, dyslipidemia, and cardiac disease.</span></p> <p class="MsoNormal"><strong><span>Objective: </span></strong><span>To evaluate the clinical outcomes of the CDC Panchakarma Protocol with Prameha Diet Box on glycemic control, anthropometric parameters, and blood pressure in T2DM patients at the Dombivali East clinic.</span></p> <p class="MsoNormal"><strong><span>Methods: </span></strong><span>Retrospective observational study of 62 T2DM patients (29 male, 33 female; mean age 49.3±12.6 years) treated at the Dombivali East Ayurvedic clinic (April 2025–March 2026). Patients received CDC-SP (BMI ≥23 kg/m², n=54) or CDC-KP (BMI <23 kg/m², n=8) therapy alongside the Prameha Diet Box and individualized herbal medications. Paired t-tests compared baseline and post-treatment values; p<0.05 was significant.</span></p> <p class="MsoNormal"><strong><span>Results: </span></strong><span>Highly significant improvements were observed in HbA1c (8.63±2.02% → 7.28±1.76%; Δ −1.36%; p<0.001), RBS (202.1 → 165.9 mg/dL; Δ −36.1 mg/dL; p=0.002), body weight (Δ −1.57 kg; p<0.001), and BMI (Δ −0.71 kg/m²; p<0.001). Systolic blood pressure showed a marginally significant reduction (Δ −5.42 mmHg; p=0.049). Post-treatment, 46.8% of patients achieved HbA1c <7.0% and 74.2% achieved <8.0%.</span></p> <p><strong><span>Conclusion: </span></strong><span>The CDC Panchakarma Protocol produced clinically and statistically significant improvements in glycemic control and anthropometric parameters in a T2DM cohort with complex comorbidities. The marginally significant SBP reduction is notable given the cardiovascular burden in this cohort. Prospective controlled trials are warranted to establish efficacy in this high-risk population.</span></p>